Medical Device

New Preservative-Free and pH-Balanced Products Formulated for Irritated, Dry Eyes Now Rolling out to Major U.S. Retailers - Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. today announced the U.S. launch of Biotrue ® Hydration Boost Lubricant Eye Drops and Biotrue ® Micellar Eyelid Cleansing Wipes. Both products are preservative-free and uniquely formulated with naturally ...

New Preservative-Free and pH-Balanced Products Formulated for Irritated, Dry Eyes

Now Rolling out to Major U.S. Retailers

- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health"), today announced the U.S. launch of Biotrue ® Hydration Boost Lubricant Eye Drops and Biotrue ® Micellar Eyelid Cleansing Wipes. Both products are preservative-free and uniquely formulated with naturally inspired ingredients to relieve symptoms associated with irritated, dry eyes.

"One of the major culprits of dry eyes, which is one of the most common eye conditions in the United States 1 , is our increasing usage of digital devices. We developed Biotrue ® Hydration Boost Lubricant Eye Drops and Biotrue ® Micellar Eyelid Cleansing Wipes to provide instant moisture to help relieve dry, digital-device-weary eyes," said Joe Gordon , U.S. president, Bausch + Lomb. "Inspired by the biology of the eye, both products are free of preservatives and are pH-balanced."

Biotrue ® Hydration Boost Lubricant Eye Drops, which can be used while wearing soft contact lenses,* provide instant moisture and relief for irritated, dry eyes. These eye drops are pH-balanced to match healthy tears with ingredients that include an electrolyte, a component of natural, healthy tears, an antioxidant, to protect against free radicals, and hyaluronan (HA) 2 , a moisturizer found naturally in tears.

For some patients, eyelid buildup can be associated with irritated, dry eyes. Bausch + Lomb developed Biotrue ® Micellar Eyelid Cleansing Wipes to gently cleanse and hydrate the eyelid area to help eyes feel more comfortable. Similar to the Biotrue ® Hydration Boost Lubricant Eye Drops, the cleansing wipes are formulated with ingredients that include HA and an electrolyte as well as a micellar cleanser comprised of a naturally derived surfactant for gentle cleansing and aloe, licorice and dandelion root extract, which are naturally soothing.

"Many of my patients report having tired and irritated eyes at the end of the day, which is typically the result of prolonged digital device usage that can lead to eye dryness," said Jennifer Tsai , O.D., and founder, Line of Sight, New York . "The availability of Biotrue ® Hydration Boost Lubricant Eye Drops and Biotrue ® Micellar Eyelid Cleansing Wipes offers two convenient, over-the-counter options that I look forward to offering my patients to help relieve the symptoms of their dry, digitally irritated eyes."

Biotrue ® Hydration Boost Lubricant Eye Drops and Biotrue ® Micellar Eyelid Cleansing Wipes will be available for purchase in the eye care aisle or online at most national retailers, including Walgreens, CVS, Walmart, Target, Rite Aid and Amazon. Both will have a manufacturer's suggested retail price as low as $11.99 .

For more information on the Biotrue ® family of products, visit www.biotrue.com .

About Bausch + Lomb
Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., is solely focused on helping people see better to live better. Its core businesses include over-the-counter products, dietary supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry, which is available in approximately 100 countries. For more information, visit www.bausch.com .

About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn .

Forward-looking Statements
This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch Health, including but not limited to its project development timelines, and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

References
1. Multi-sponsor Surveys, Inc., The 2017 Gallup Study of Dry Eye Sufferers.
2. HA is sourced from a large-scale natural fermentation process.

*Based on standardized testing of soft contact lenses. Not meant to lubricate or rewet lenses.

®/TM are trademarks of Bausch & Lomb Incorporated or its affiliates.
Any other product/brand names and/or logos are trademarks of the respective owners.
© 2021 Bausch & Lomb Incorporated or its affiliates.
BTW.0026.USA.21

Bausch Health Investor Contact:

Bausch Health Media Contact:

Arthur Shannon

Lainie Keller

arthur.shannon@bauschhealth.com

lainie.keller@bauschhealth.com

(514) 865-3855

(908) 927-1198

(877) 281-6642 (toll free)


Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/bausch--lomb-launches-biotrue-hydration-boost-lubricant-eye-drops-and-biotrue-micellar-eyelid-cleansing-wipes-301331203.html

SOURCE Bausch Health Companies Inc.

News Provided by PR Newswire via QuoteMedia

Thermo Fisher Scientific Completes Acquisition of PPD, Inc.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has completed its acquisition of PPD, Inc. (Nasdaq: PPD), a leading global provider of clinical research services to the biopharma and biotech industry, for $17.4 billion .

"We are very excited to officially welcome our PPD colleagues to Thermo Fisher Scientific," said Marc N. Casper , chairman, president and chief executive officer of Thermo Fisher Scientific. "Expanding our value proposition for our biotech and pharmaceutical customers with the addition of PPD's leading clinical research services advances our work in bringing life-changing therapies to market, benefitting patients around the world."

Keep reading... Show less
UPDATED - Leveljump Healthcare Corp. Announces 14.6% Minority Investment in Real Time Medical Approved by TSXV and Closed

UPDATED - Leveljump Healthcare Corp. Announces 14.6% Minority Investment in Real Time Medical Approved by TSXV and Closed

LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("Leveljump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce that, it has received TSXV approval, and has closed its acquisition of a 14.6% minority equity interest in Real Time Medical Inc. ("RTM"), a private Ontario company, in exchange for 2,494,576 units (a "Unit") of Leveljump. Each Unit will be issued at a price of $0.66 per Unit with each Unit being comprised of three (3) Leveljump common shares at a deemed price of $0.22 per share and one (1) share purchase warrant of Leveljump, each warrant entitling the holder to acquire one additional common share of Leveljump at a price of $0.35 per common share on or before December 31, 2023.

The equity interest in RTM was acquired through a mini-tender offer to the shareholders of RTM dated November 1, 2021 whereby JUMP offered to acquire up to 19.9% of RTM in exchange for the Units. The holders of the RTM shares who have tendered are all accredited investors.

Keep reading... Show less
Leveljump Healthcare Strengthens Board of Directors

Leveljump Healthcare Strengthens Board of Directors

LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("Leveljump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce new additions to its board of directors and its advisory board.

Gary Prihar - Director

Keep reading... Show less
ALR Technologies and Infinovo Sign Memorandum of Understanding to Manufacture World's First CGM for Diabetic Pets

ALR Technologies and Infinovo Sign Memorandum of Understanding to Manufacture World's First CGM for Diabetic Pets

ALR Technologies ("ALRT" or the "Company") (OTCQB: ALRT), the diabetes management company, is pleased to announce the signing of a Memorandum of Understanding ("MOU") with Infinovo Medical Co. Ltd for a global supply agreement of their P3 Continuous Glucose Monitor (CGM) for use by ALRT in the animal health sector.

Under the terms of the MOU, ALR Technologies and Infinovo will collaborate to integrate Infinovo's P3 CGM with ALRT's proprietary GluCurve platform. The Company expects to begin testing the GluCurve Pet CGM in veterinary clinics in late December 2021 or early January 2022. The testing is scheduled to complete by the end of February 2022.

Keep reading... Show less

Medtronic Hugo robotic-assisted surgery system receives Health Canada licence, further enabling access to robotic-assisted surgery in Canada

Medtronic Canada ULC, a subsidiary of Medtronic plc (NYSE: MDT), the world's leading medical technology company, announced it has received a Health Canada licence for the Hugo™ robotic-assisted surgery (RAS) system for use in use in urologic and gynecologic laparoscopic surgical procedures, which make up about half of all robotic procedures performed today. 1

Keep reading... Show less

APMA Grants Seal of Approval for JUBLIA® Topical Solution, 10%

Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health") and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced JUBLIA ® (efinaconazole) Topical Solution, 10%, a treatment for onychomycosis, a fungal infection of the toenails, has received the American Podiatric Medical Association (APMA) Seal of Approval. The APMA Seal of Approval is granted to products that promote good foot health and are of significant value when used in a consistently applied program of daily foot care and regular professional treatment.

Keep reading... Show less

Top News

Related News